CEO Corner
CEO Corner articles are written by presidents or CEOs of biopharmaceutical or medical device companies that create a drug or device. These articles discuss global industry trends, experiences, and challenges that biopharma CEOs and presidents can relate to and should be aware of. To submit a CEO Corner article, please follow these guidelines.
-
How To Lead a Company That's Disrupting An Industry
Pacira BioSciences CEO Frank D. Lee shares three core tenants to improve biopharmaceutical company leadership, especially companies with products capable of disrupting an established therapeutic area.
-
From Bike Mechanic To Surgeon To CEO
InflaRx cofounder and CEO Niels Riedemann, M.D. shares the overarching pillars that have shaped his career as a physician, surgeon, and biopharmaceutical leader.
-
Navigating Growth In Biotech: A First-Person Insight
Five attributes are essential for emerging biotech companies to thrive and grow in what will be a challenging financing environment for the foreseeable future. These attributes also serve as a proxy for creating long-term, sustainable value.
-
Delivering The Next Evolution In Immuno-Oncology
To continue the momentum created by new discoveries and treatments for cancer patients, drug developers need a strong and focused corporate culture, employees willing to challenge established norms, and a system for prioritizing development candidates guided by science and patient needs.
-
Facing The Drug Launch Challenge As A New CEO
Economic instability, geopolitical struggles, market access, pricing, and regulatory differences — among many other issues — can present themselves at any time before, during, or after the launch. What is important is how a CEO manages the steps toward launch success.
-
Essential Elements Of Becoming A Successful CEO
In this article, I address what it takes to succeed as a CEO by sharing insights and learnings from my own career in the hope that my experiences will offer some valuable guidance to those who aspire to become CEOs.
-
Making The Jump From Big Pharma To Biotech
When a recruiter presented me with an opportunity to become CEO of a small but rising publicly listed biotech in my native Canada, I had to give it a lot of thought. Although I loved my job, I was a bit itchy to make not just a career move, but a life move.
-
From Science To CEO: Advice For First-Time Founders
Although it’s still early in my transition from a researcher in a lab to CEO, I think it’s worth sharing the playbook I wish I had when I started out.
-
My Journey From "Science Guy" To CEO
I am a big believer in refining one's personal brand and even reinventing yourself to create opportunities for personal growth. During my career, some key truths and learnings have emerged that I feel privileged to share, and I hope these will be insightful and helpful.
-
Driving And Sustaining Innovation In Biopharma Today
We’ve arrived at a critical window for innovation in rare disease that must be treated with the same caliber and urgency that we saw nearly three years ago at the onset of the COVID-19 pandemic.
IN THIS MONTH'S ISSUE
- Gene Editing Versus Gene Therapy: Is There A Difference?
- The Ozempic Dilemma: What Makes A Dual Brand Approach Viable?
- Ensuring Diversity And Accessibility In Neurological Research
- A New Year's Resolution Suggestion For The FDA
- Pharma's Customer Engagement Evolution: Is Your Data Governance Keeping Pace?
BEYOND THE PRINTED PAGE
-
2023 Manufacturing And Supply Chain Outlook: Additional Insights12/16/2022
Additional executive responses to our 2023 manufacturing and supply chain outlook questions.
-
2023 Finance And Funding Outlook: Additional Insights Part 212/9/2022
Additional experts weigh in on Life Science Leader's 2023 finance and funding outlook questions.
-
2023 Finance And Funding Outlook: Additional Insights Part 112/2/2022
Biopharma executives offer options, tips and strategies for navigating finance and funding challenges in 2023.